Litigation Details for Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
✉ Email this page to a colleague
Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-05-08 |
Court | District Court, D. Delaware | Date Terminated | 2020-09-11 |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | None | Referred To | |
Patents | 6,841,716; 8,231,906; 9,724,310; 9,730,900; 9,833,419 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC
Details for Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2019-03-08 | 112 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,730,900 (the "' 900 Patent"), 9,724,310 (the '"…quot; 310 Patent"), and 9,833 ,419 (the '" 419 Patent") (collectively, "patents-in-suit…-suit" or "asserted patents"). (D.I. 83 at 3) The patents-in-suit relate "to transdermal…; It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification | External link to document |
2018-06-01 | 13 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,841,716 . (Wilson, Samantha… 11 September 2020 1:18-cv-00699 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
2021-09-03 | 249 | Order - -Memorandum and Order | of U.S. Patent Nos. 9,833,419 (the “419 patent”), 9,730,900 (the “’900 patent”), and 9,724,310 (the “°… infringes the °419 patent; (2) Amneal’s product does not infringe the °900 patent under the doctrine … does not infringe the ’310 patent under the DOE; (4) the asserted patents are invalid for lack of enablement…the asserted patents claimed transmucosal patches; (2) the specification of the patents contained no …notified Innovation that the ’140 patent was legally insufficient either as patent ineligible subject matter | External link to document |
2018-07-05 | 25 | Consent Judgment - Proposed | PROPOSED CONSENT JUDGMENT with respect to U.S. Patent No. 6,841,716, by Hisamitsu Pharmaceutical Co. Inc.. (… 11 September 2020 1:18-cv-00699 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |